Teva says it is still hopeful that it can resolve US price-fixing allegations “in a positive way,” insisting that it remains “in dialog” with the US Department of Justice over wide-ranging allegations that place the Israeli firm at the center of a pricing conspiracy.
Teva Still Hopes To Reach Deal On US Price-Fixing Allegations
Israeli Firm Remains ‘In Dialog’ With DoJ Over Conspiracy Claims
Teva says it remains hopeful that it can resolve US price-fixing allegations “in a positive way” with the US Department of Justice, but acknowledges that the matter could go all the way to trial.
More from Legal & IP
More from Generics Bulletin
• By
South Korea’s Celltrion has doubled down on its efforts in further building its pipeline, eyeing a target of 22 commercialized products by 2030 while also aiming to submit INDs for 13 novel compounds.
• By
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
• By
The EMA’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam. Generics Bulletin discusses the new draft reflection paper and its significance for industry, reports on reactions from the event, and reveals the next steps unveiled by EMA officials.